All In Biotech

Drug Trial Radar · NCT01709214

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

A Randomized, Double-Blind, Placebo- and Active Controlled Study to Evaluate the Safety and Efficacy of GRT6005 in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 619 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

619

Actual

Start

Dec 4, 2012

Primary completion

Apr 2014

Study completion Apr 4, 2014

Sponsor

Lead sponsor
Tris Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Forest Laboratories
First posted
Oct 18, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of GRT6005 compared to placebo in patients with moderate to severe chronic pain due to osteoarthritis (OA) of the knee. This study includes a maximum 21 day Screening Period followed by a 15-week Double-blind Treatment Period and a 4-7 day Safety Follow-up period. Patients who are eligible for the Double-blind Treatment Period will be randomized to one of following treatment groups: GRT6005 high-dose range (400, 600 or 800 mcg), GRT6005 low-dose range (200, 300 or 400 mcg), oxycodone controlled release (CR) dose range (10, 20, 30, 40 or 50 mg) or placebo.

Conditions

  • Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Interventions

  • Cebranopadol (GRT6005) Low-Dose RangeDrug

    Capsules

  • Cebranopadol (GRT6005) High-Dose RangeDrug

    Capsules

  • PlaceboDrug

    Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules

  • Oxycodone CRDrug

    Capsules containing oxycodone CR 10 or 20 milligrams

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the weekly average of the daily average pain ratingTime frame: Baseline to end of treatment (Week 15)

Locations

83 sites in 1 country. Site status is shown where the registry gives one.

  • Site 051

    Birmingham, Alabama

  • Site 022

    Birmingham, Alabama

  • Site 031

    Huntsville, Alabama

  • Site 005

    Phoenix, Arizona

  • Site 018

    Phoenix, Arizona

  • Site 070

    Phoenix, Arizona

  • Site 028

    Tucson, Arizona

  • Site 081

    Chino, California

  • Site 030

    El Cajon, California

  • Site 039

    Fair Oaks, California

  • Site 061

    Fresno, California

  • Site 084

    North Hollywood, California

  • Site 080

    Roseville, California

  • Site 004

    Sacramento, California

  • Site 044

    San Diego, California

  • Site 043

    Tustin, California

  • Site 010

    Walnut Creek, California

  • Site 027

    Westlake Village, California

  • Site 011

    Bradenton, Florida

  • Site 071

    Clearwater, Florida

  • Site 090

    Edgewater, Florida

  • Site 060

    Jacksonville, Florida

  • Site 015

    Jupiter, Florida

  • Site 013

    Miami, Florida

  • Site 003

    New Port Richey, Florida

  • Site 012

    Ocala, Florida

  • Site 032

    Orlando, Florida

  • Site 025

    Ormond Beach, Florida

  • Site 058

    Pembroke Pines, Florida

  • Site 091

    Pinellas Park, Florida

  • Site 007

    Sarasota, Florida

  • Site 052

    Marietta, Georgia

  • Site 033

    Perry, Georgia

  • Site 073

    Stockbridge, Georgia

  • Site 086

    Chicago, Illinois

  • Site 041

    Indianapolis, Indiana

  • Site 085

    Valparaiso, Indiana

  • Site 088

    Towson, Maryland

  • Site 077

    Wheaton, Maryland

  • Site 083

    New Bedford, Massachusetts

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.